消化道肿瘤患者与健康人群粪便菌群差异分析

Gut Microbiome Differences between Gastrointestinal Cancer Patients and Healthy People

目的比较食管癌、胃癌、结直肠癌患者之间,及不同消化道肿瘤患者与健康人群之间粪便菌群的差异。方法采用16SrRNA的方法,对13例食管鳞癌、23例胃癌、6例结直肠癌患者,49例健康人的粪便菌群差异进行分析。结果肿瘤组患者粪便菌群中双歧杆菌、普拉梭菌、伶俐瘤胃球菌较健康对照人群丰度明显减低(P均<0.05);厚壁菌门、放线菌门的部分菌种在食管癌、胃癌患者粪便中较健康人群显著减少(P均<0.05),部分与肠癌组一致;抗肿瘤治疗、抗生素、乳酸菌制剂均对肿瘤患者的粪便菌群产生影响。结论食管癌、胃癌患者粪便中以厚壁菌门、放线菌门消耗为主的菌群组成模式及部分标志性菌种与肠癌的相似性,提示这些细菌与上消化道肿瘤的发生发展可能相关。

Objective To compare the differences in fecal flora among patients with esophageal cancer,gastric cancer,or colorectal cancer and between patients with gastrointestinal tumors and healthy people. Methods The 16S rRNA method was used to analyze the differences in fecal flora among 13 patients with esophageal squamous cell carcinoma,23 patients with gastric cancer,6 patients with colorectal cancer,and 49 healthy persons. Results Bifidobacterium, Faecalibacterium prausnitzii ,and Ruminococcus callidus were less abundant in the fecal flora of cancer patients than in those of healthy controls(all P <0.05).Some species of Firmicutes and Actinobacteria were significantly reduced in the feces of patients with esophageal cancer or gastric cancer than in healthy people( P <0.05),whereas others showed consistency with the intestinal cancer group.Anti-tumor treatment,antibiotics,and lactic acid could affect the fecal flora of cancer patients. Conclusion The gut microbiota compositions(mainly Firmicutes and Actinobacteria )and some specific bacteria species in the feces of patients with esophageal cancer and gastric cancer are similar to those in the feces of patients with intestinal cancer,suggesting these bacteria may be involved in the development of upper gastrointestinal tumors.